Information Provided By: 
Fly News Breaks for March 2, 2020
BEAM
Mar 2, 2020 | 06:32 EDT
Jefferies analyst Michael Yee initiated coverage of Beam Therapeutics with a Buy rating and $32 price target. Beam is a next-generation gene editing platform utilizing "single base pair" correction which could lead to improved editing and safety, Yee tells investors in a research note. Although early, it's like gene therapy a few years ago playing out and gene editing and Beam Therapeutics should go up as the industry gets a lot more data over next 12-24 months, says the analyst.
News For BEAM From the Last 2 Days
There are no results for your query BEAM
